-transparent.png){kind=logo}
The effect of deoxyguanosine on mitogen- and antigen-induced proliferation of peripheral blood lymphocytes from healthy donors was studied. Deoxyguanosine was found to inhibit the proliferative response to mitogens and antigens. Concentrations of deoxyguanosine causing 50% inhibition of the proliferation proved to be dependent on the activity of catabolic enzymes, such as purine nucleoside phosphorylase (PNP), in sera used in the culture media. The inhibitory effect of deoxyguanosine on phytohemagglutinin (PHA)-induced cell proliferation was prevented by deoxycytidine as well as by hypoxanthine. These findings were analyzed further by determination of intracellular (deoxy)-nucleotide levels. Stimulation of lymphocytes by PHA in the presence of deoxyguanosine leads to intracellular accumulation of dGTP. The presence of hypoxanthine in addition to deoxyguanosine abolished the inhibitory effect but did not prevent dGTP accumulation. On the other hand, the addition of deoxycytidine in combination with deoxyguanosine did not lead to intracellular accumulation of detectable amounts of dGTP, but only gave partial protection against the toxic effect. Furthermore, guanosine inhibited mitogen-induced cell proliferation to the same extent as did deoxyguanosine provided that the culture media were supplemented with pretreated fetal calf serum. Peripheral blood lymphocytes of a PNP-deficient or a HGPRT-deficient patient in cultures stimulated with PHA or pokeweed mitogen were resistant to the inhibitory effects of guanosine and were less sensitive to deoxyguanosine than cells of normal donors. The present results clearly show the involvement of two pathways contributing to deoxyguanosine-mediated inhibition of the proliferation of normal lymphocytes, i.e., on the one hand degradation of deoxyguanosine by PNP, salvage of guanine by HGPRT, and (possibly) phosphorylation of GMP eventually leading to GTP, and on the other hand formation of dGTP by direct phosphorylation of deoxyguanosine by deoxycytidine kinase.
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
March 1985,
Clinical and experimental immunology,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
January 1984,
European journal of clinical pharmacology,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
July 1988,
Experimental eye research,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
October 1989,
Transplantation proceedings,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
December 1978,
Cancer research,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
January 1986,
Comparative biochemistry and physiology. A, Comparative physiology,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
January 1976,
Transplantation,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
January 1986,
Transactions of the Royal Society of Tropical Medicine and Hygiene,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
April 1989,
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
L J Spaapen, and
G T Rijkers, and
G E Staal, and
G Rijksen, and
S K Wadman, and
J W Stoop, and
B J Zegers
March 1985,
Clinical and experimental immunology,
